Quick Answer
Crinetics Pharmaceuticals, Inc. reported Diluted EPS of $4.95 per share (loss) for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.95 | -34.1% |
| 2024 | -$3.69 | +0.0% |
| 2023 | -$3.69 | -17.1% |
| 2022 | -$3.15 | -12.5% |
| 2021 | -$2.80 | -15.7% |
| 2020 | -$2.42 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.38 | -43.7% | -12.2% |
| June 30, 2025 | -$1.23 | -30.9% | -18.3% |
| March 31, 2025 | -$1.04 | -11.8% | -8.3% |
| September 30, 2024 | -$0.96 | +5.0% | -2.1% |
| June 30, 2024 | -$0.94 | +0.0% | -1.1% |
| March 31, 2024 | -$0.93 | -9.4% | +7.9% |
| September 30, 2023 | -$1.01 | -29.5% | -7.4% |
| June 30, 2023 | -$0.94 | -16.0% | -10.6% |
- Crinetics Pharmaceuticals, Inc. showed a decrease of -34.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Crinetics Pharmaceuticals, Inc.’s diluted eps has declined by 104.5% (from $2.42 per share (loss) to $4.95 per share (loss)).
- The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: